POEMs

No Benefit to Addition of Stenting for Treatment of Atherosclerotic Renal Artery Stenosis

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2014 Apr 1;89(7):576-578.

Clinical Question

Does the use of renal artery stenting combined with aggressive medical therapy improve outcomes in patients with severe atherosclerotic renal artery stenosis?

Bottom Line

In patients with severe atherosclerotic renal artery stenosis and hypertension or chronic kidney disease, renal artery stenting does not provide an additional benefit when added to comprehensive medical therapy that includes blood pressure and diabetes mellitus management, and antiplatelet and lipid therapies. (Level of Evidence = 1b)

Synopsis

These investigators enrolled 947 patients with severe atherosclerotic renal artery stenosis (60% stenosis or more). Eligible patients also had systolic hypertension while taking two or more antihypertensive medications or chronic kidney disease. Using concealed allocation, patients were randomized to receive stenting plus medical therapy or medical therapy alone. Medical management included antiplatelet agents, antihypertensives, and lipid-lowering therapies. Specifically, all patients received candesartan (Atacand) with or without hydrochlorothiazide, as well as the combination pill amlodipine/atorvastatin (Caduet). Diabetes was managed according to clinical practice guidelines. The two groups had similar comorbidities at baseline. Overall, 90% of patients in each group had hyperlipidemia and approximately 30% had diabetes. The primary outcome was a composite of death from cardiovascular or renal causes, stroke, myocardial infarction, hospitalization for acute heart failure, worsening renal insufficiency, or the need for permanent dialysis. At a median follow-up of 43 months, there was no significant difference detected between the two groups in the composite outcome (hazard ratio = 0.95; 95% confidence interval, 0.76 to 1.17) or its individual components. All-cause mortality was also similar (hazard ratio = 0.80; 95% confidence interval, 0.58 to 1.12).

Study design: Randomized controlled trial (nonblinded)

Funding source: Industry plus government

Allocation: Concealed

Setting: Outpatient (any)

Reference: Cooper CJ, Murphy TP, Cutlip DE, et al.; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med.. 2014; 370( 1): 13– 22.

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.



 

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article